Synopsis
Magnetic resonance imaging
(MRI) plays critical roles in the diagnosis of hepatobiliary diseases. Compared with other hepatic imaging modalities, contrast-enhanced MRI offers more comprehensive evaluation of
the hepatobiliary diseases. In this lecture, I am going to discuss the key
features of the different types of contrast agents, with special emphasis on pharmacokinetic
features of a new hepatobiliary MR contrast agent. In addition, I will address
the optimized protocols according to the type of gadolinium contrast agent. For
gadoxetate disodium, the potential advantages for diagnosing liver malignancies
and for evaluation of hepatocarcinogenesis will be addressed via
radiology-pathology correlation and also its caveats will be discussed with
typical cases.Addressing Clinical Challenges in the Body with MRI: Contrast Agents
Magnetic resonance imaging
(MRI) plays critical roles in the diagnosis of hepatobiliary diseases and
staging of hepatobiliary malignancies. In this lecture, I am going to discuss the
key features of the different types of contrast agents, with special emphasis
on pharmacokinetic features of a new hepatobiliary MR contrast agent. In
addition, I will address the optimized protocols according to the type of
gadolinium contrast agent. For gadoxetate disodium, the potential advantages
for diagnosing liver malignancies and for evaluation of hepatocarcinogenesis
will be addressed via radiology-pathology correlation and also its caveats will
be discussed with typical cases. Finally, I will review
the guidelines in the imaging diagnosis of HCCs and the challenging issues that
remain.
Acknowledgements
No acknowledgement found.References
1. Guglielmo FF, Mitchell DG, Gupta S.
Gadolinium contrast agent selection and optimal use for body mr imaging. Radiol
Clin North Am 2014;52:637-656
2. Bashir MR. Magnetic
resonance contrast agents for liver imaging. Magn Reson Imaging Clin N Am
2014;22:283-293
3. Guglielmo FF,
Mitchell DG, Roth CG, Deshmukh S. Hepatic mr imaging techniques, optimization,
and artifacts. Magn Reson Imaging Clin N Am 2014;22:263-282
4. Neri E, Bali MA,
Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC et al. Esgar consensus statement
on liver mr imaging and clinical use of liver-specific contrast agents. Eur
Radiol 2015